Ostalo
Biologic agents and oral diseases; therapeutic prospects and restrictions
Eleni A Georgakopoulo
; 1ST Uiversity Dermatology Clinic ,Medical School of Athens Greece, "A. Sygros" Hospital Oral medicine Department
Dimitrios Andreadis
; 1st Dermatology Clinic “A. Sygros” Hospital, Medical School, National and Kapodistrian University of Athens, Greece
Efthymios Arvanitidis
; Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece
Panagiota Loumou
; Department of Dermatology, “Attiko” Hospital, Medical School, University of Athens, Greece
Sažetak
Abstract: Biologic agents (BAs) are synthesized by the products of living organisms and are widely used in the treatment of inflammatory and neoplastic conditions with favorable results. The purpose of this review is to provide an update of the biologic agents reported to have been used in treatment of diseases that affect the oral mucosa, as off-label indications. Identification of cases studies referring to the use of biologic agents in patients with Sjögren syndrome (including patients with MALT-lymphomas), pemphigus (vulgaris, foliaceous, paraneoplastic), mucous membrane pemphigoid, oral lichen planus, Behcet’s disease, orofacial granulomatosis, and recurrent aphthous ulceration (RAU), was achieved using Pubmed –Medline database , performing both electronic search (with key words infliximab, etanercept, adalimumab, rituximab, efalizumab, epratuzumab and alefacept , oral diseases, oral manifestations, dermatologic diseases, immune mediated diseases, biologic agents , anti-TNF agents, monoclonal antibodies, anti-B cell agents, anti T-cell agents ) and hand search to identify articles that referred specifically to patients with oral involvement.. According to the literature so far the use of BAs in patients that suffered from refractory forms of the immune-related diseases of the oral mucosa seems in general a clinically encouraging therapeutic option, but not without side effects including secondary infections, and also with a questionable economic cost-effect. Indeed, more studies in larger groups and longer period of time are required in order to confirm their efficacy and safety.
Ključne riječi
Hrčak ID:
101616
URI
Datum izdavanja:
10.5.2013.
Posjeta: 1.467 *